Elemental analysis supports elemental impurity control, foreign-particle investigations, inorganic phase context, contamination, and material verification.
This decision-focused guide explains the scientific measurement basis, when to use it, its limitations, sample amount considerations, competing methods, FDA-facing concerns, and common mistakes.
Elemental analysis determines which elements are present and, where appropriate, how much of each is present. ICP-MS is highly sensitive for trace elements; SEM/EDX localizes elements on particles; XRF provides non-destructive bulk elemental information; PIXE can provide sensitive non-destructive multi-element analysis.
Use elemental analysis for USP <232>/<233> and ICH Q3D elemental impurities, foreign particles, corrosion products, inorganic contaminants, device/coating investigations, raw materials, catalysts, minerals, and elemental mapping.
ICP-MS is destructive and needs digestion or suitable prep. EDX has detection and vacuum/preparation limits, and light/volatile species can be difficult. XRF may struggle with light elements or matrix effects. Elemental data often do not identify molecular species.
Amount depends on method, target elements, detection limits, and whether the sample must be retained. Particle-level SEM/EDX can use small particles; ICP-MS and XRF needs depend on preparation and regulatory limits.
XRF, ICP-MS, ICP-OES, SEM/EDX, PIXE, chromatography, MS, XRPD, FTIR/Raman, and microscopy can compete or complement one another depending on whether the question is bulk composition, trace quantitation, molecular identity, or spatial distribution.
For pharmaceuticals, FDA and ICH expectations focus on risk-based elemental-impurity control under ICH Q3D and USP <232>/<233>, including PDE limits, method suitability, specificity, accuracy, precision, and matrix control.
Common mistakes include using bulk elemental data to infer molecular identity, ignoring sample contamination during prep, failing to distinguish substrate from particle, choosing a method with insufficient sensitivity, and not linking results to ICH Q3D risk.
Triclinic uses elemental analysis to investigate elemental impurities, residual catalysts, inorganic contaminants, raw-material differences, and composition questions that affect safety, quality, or process understanding. Real-world applications include ICH Q3D-style risk support, contamination investigations, excipient and API comparability, metal-containing materials, and cases where SEM/EDX, XRF, ICP-MS, or related methods are needed to connect elements to particles, surfaces, or bulk composition.
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| ICP-MS trace-element platform | Thermo Fisher Scientific iCAP RQ ICP-MS, single-quadrupole ICP-MS | Microwave digestion sytems available. Trace and ultra-trace elemental analysis, inorganic impurity testing, USP <232>/<233> and ICH Q3D support, and multi-element method development/validation. |
| SEM/EDX platform | Thermo Phenom XL SEM/EDX with fully integrated elemental and BSE detector | Localized elemental analysis, foreign-particle examination, BSE contrast, and contaminant investigations. |
| SEM/EDX detector suite | Oxford INCA PentFETx3 energy-dispersive X-ray spectroscopy system | EDX spectra, elemental maps, and spot/region composition data. |
| XRF platform | Panalytical Epsilon 4 ED-XRF spectrometer | Non-destructive elemental analysis from carbon to americium, with concentration range from sub-ppm to 100 wt%. |
| PIXE capability | Proton-induced X-ray emission workflow | Non-destructive multi-element analysis from sodium to uranium, surface-sensitive analysis, and ppm-level elemental screening. |
This example illustrates the difference between bulk elemental composition and particle-level evidence. The legacy elemental-analysis page describes SEM/EDX use for localized elemental analysis, contaminant identification, and elemental mapping. The first figure supports a foreign-particle investigation by comparing selected analysis regions and spot data. The second figure shows how false-color elemental mapping can separate particle types within a mixture.
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
Author: International Council for Harmonisation
Publication date: 2022
Abstract: ICH Q3D(R2) provides the risk-management framework for assessing and controlling elemental impurities in drug products. It is the regulatory anchor for elemental-impurity testing, method selection, and justification of ICP-MS, XRF, or other elemental-analysis strategies.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Author: Melanie Bevill, Chris Seadeek, Nico Setiawan, Shawn Comella, Blaise Mibeck, and Steef Boerrigter
Publication date: November 2023
Abstract: This Triclinic application note links solid-form screening and selection to crystallinity, stability, solubility, hygroscopicity, manufacturability, regulatory needs, and IP objectives. It supports choosing analytical techniques based on the development decision rather than a fixed instrument list.
Use this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View technique
Tell Triclinic what sample you have, what decision the data must support, what prior data are available, and whether cGMP, release, validation, or regulatory documentation is required.
